 These ligands should behave as antagonists in the prostate with either no activity or agonist activity in other target tissues, so as to have little or no effects in the anabolic tissues or central nervous system (CNS).However discovering this new class of ligands might be challenging because the molecular mechanism of AR action is not well understood.Several mechanisms have been proposed to achieve this tissue selectivity of AR ligands.